SHR-A2009

N/A

Report date: 2026/05/12 20:00:17

Base Information

Drug NameSHR-A2009
Drug Alias NameSHR-A2009
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 modulators
TargetsReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth KoreaMainland ChinaJapan
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSuzhou Suncadia Biopharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHenan Provincial Cancer HospitalFudan UniversityShandong Shengdi Pharmaceutical Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A